152P TACTI-003 Cohort B: Eftilagimod alpha (Soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head & neck squamous cell carcinoma with PD-L1 negative
Year: 2024
Type: article
Abstract: Eftilagimod alpha (E) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell activation & T-cell (CD4/CD8) recruitment/activation. Prior results from a phase II study of E plus pembrolizumab (P) as a second-line therapy in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) led to promising response rates across all PD-L1 strata (TACTI-002; NCT03625323). We report updated results from the PD-L1 negative (CPS <1) Cohort B of the TACTI-003 study in 1st line HNSCC (NCT04811027).
Source: Immuno-Oncology Technology
Institutions: University College London Hospitals NHS Foundation Trust, University College London, Universität Ulm, University Hospital Ulm, The Christie NHS Foundation Trust, Institute of Oncology Prof. Dr. Ion Chiricuta, Copenhagen University Hospital, Rigshospitalet, Vall d'Hebron Institute of Oncology, Hospital Universitario Ramón y Cajal, National Center for Tumor Diseases, Nottingham University Hospitals NHS Trust, Antwerp University Hospital, Hospital Universitario Lucus Augusti, Immutep (Germany)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,170
OpenAlex ID: W4405374809